Anthera Pharmaceuticals Inc Form 8-K March 20, 2012

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of report (Date of earliest event reported): March 15, 2012

ANTHERA PHARMACEUTICALS, INC.

(Exact Name of Registrant as Specified in Charter)

Delaware (State or Other Jurisdiction of Incorporation) 001-34637 (Commission File Number)

20-1852016 (I.R.S. Employer Identification No.)

25801 Industrial Boulevard, Suite B, Hayward, California

(Address of Principal Executive Offices)

94545 (Zip Code)

Registrant s telephone number, including area code (510) 856-5600

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 8.01	Other Events.			
On March 15, 2 Exhibit 99.1.	2012, Anthera Pharmaceuticals, Inc. (the	Company	y) issued a press release. A copy of the press release is furnished herewith	ı as
Item 9.01	Financial Statements and Exhibits.			
(d) Exhibits				
Exhibit No. 99.1	Press Release dated March 15, 2012		Description	
			2	

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Anthera Pharmaceuticals, Inc.

Date: March 20, 2012 By: /s/ Christopher P. Lowe

Christopher P. Lowe Chief Financial Officer

3

Exhibit Index

Exhibit No. Description

99.1 Press Release dated March 15, 2012

4